Detalhe da pesquisa
1.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142371
2.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet
; 387(10024): 1163-77, 2016 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26719232
3.
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Eur Urol Oncol
; 1(6): 449-458, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31158087
4.
Use of systemic therapy in the treatment of choroidal metastases from breast cancer.
BMJ Case Rep
; 20142014 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25427924